scholarly journals Potential for cell therapy in Parkinson's disease using genetically programmed human embryonic stem cell-derived neural progenitor cells

2014 ◽  
Vol 522 (12) ◽  
pp. 2845-2856 ◽  
Author(s):  
Rajesh Ambasudhan ◽  
Nima Dolatabadi ◽  
Anthony Nutter ◽  
Eliezer Masliah ◽  
Scott R. Mckercher ◽  
...  
2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Miranda Robbins ◽  
Venkat Pisupati ◽  
Roberta Azzarelli ◽  
Samer I. Nehme ◽  
Roger A. Barker ◽  
...  

Abstract Background Stem cell-based therapies for neurodegenerative diseases like Parkinson’s disease are a promising approach in regenerative medicine and are now moving towards early stage clinical trials. However, a number of challenges remain including the ability to grow stem cells in vitro on a 3-dimensional scaffold, as well as their loss, by leakage or cell death, post-implantation. These issues could, however, be helped through the use of scaffolds that support the growth and differentiation of stem cells both in vitro and in vivo. The present study focuses on the use of bacterial cellulose as an in vitro scaffold to promote the growth of different stem cell-derived cell types. Bacterial cellulose was used because of its remarkable properties such as its wettability, ability to retain water and low stiffness, all of which is similar to that found in brain tissue. Methods We cultured human embryonic stem cell-derived progenitor cells on bacterial cellulose with growth factors that were covalently functionalised to the surface via silanisation. Epifluorescence microscopy and immunofluorescence were used to detect the differentiation of stem cells into dopaminergic ventral midbrain progenitor cells. We then quantified the proportion of cells that differentiated into progenitor cells and compared the effect of growing cells on biofunctionalised cellulose versus standard cellulose. Results We show that the covalent functionalisation of bacterial cellulose sheets with bioactive peptides improves the growth and differentiation of human pluripotent stem cells into dopaminergic neuronal progenitors. Conclusions This study suggests that the biocompatible material, bacterial cellulose, has potential applications in cell therapy approaches as a means to repair damage to the central nervous system, such as in Parkinson’s disease but also in tissue engineering.


2013 ◽  
Vol 198 (2) ◽  
pp. 127-138 ◽  
Author(s):  
Ruttachuk Rungsiwiwut ◽  
Chirawattana Manolertthewan ◽  
Pranee Numchaisrika ◽  
Vichuda Ahnonkitpanit ◽  
Pramuan Virutamasen ◽  
...  

2015 ◽  
Vol 2015 ◽  
pp. 1-10 ◽  
Author(s):  
Parinya Noisa ◽  
Taneli Raivio ◽  
Wei Cui

Human embryonic stem cells (hESCs) are able to proliferatein vitroindefinitely without losing their ability to differentiate into multiple cell types upon exposure to appropriate signals. Particularly, the ability of hESCs to differentiate into neuronal subtypes is fundamental to develop cell-based therapies for several neurodegenerative disorders, such as Alzheimer’s disease, Huntington’s disease, and Parkinson’s disease. In this study, we differentiated hESCs to dopaminergic neurons via an intermediate stage, neural progenitor cells (NPCs). hESCs were induced to neural progenitor cells by Dorsomorphin, a small molecule that inhibits BMP signalling. The resulting neural progenitor cells exhibited neural bipolarity with high expression of neural progenitor genes and possessed multipotential differentiation ability. CBF1 and bFGF responsiveness of these hES-NP cells suggested their similarity to embryonic neural progenitor cells. A substantial number of dopaminergic neurons were derived from hES-NP cells upon supplementation of FGF8 and SHH, key dopaminergic neuron inducers. Importantly, multiple markers of midbrain neurons were detected, includingNURR1, PITX3, andEN1, suggesting that hESC-derived dopaminergic neurons attained the midbrain identity. Altogether, this work underscored the generation of neural progenitor cells that retain the properties of embryonic neural progenitor cells. These cells will serve as an unlimited source for the derivation of dopaminergic neurons, which might be applicable for treating patients with Parkinson’s disease.


2006 ◽  
Vol 66 (13) ◽  
pp. 1489-1500 ◽  
Author(s):  
C. Eduardo Corrales ◽  
Luying Pan ◽  
Huawei Li ◽  
M. Charles Liberman ◽  
Stefan Heller ◽  
...  

2005 ◽  
Vol 19 (12) ◽  
pp. 1686-1688 ◽  
Author(s):  
Teodora Nikolova ◽  
Jaroslaw Czyz ◽  
Alexandra Rolletschek ◽  
Przemyslaw Blyszczuk ◽  
Jörg Fuchs ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document